Guidant files suit against J&J to complete merger

Share this article:
Guidant filed a federal lawsuit yesterday to force Johnson & Johnson to complete its $25.4 billion acquisition of the company, The New York Times reports.
J&J contends the deal is now void because of Guidant's financial and legal problems.
Guidant, based in Indianapolis, disclosed yesterday that the Securities and Exchange Commission has opened a formal investigation into the timing of company disclosures about problem heart devices and trading in company stock. The company is already under investigation by the FDA and the Justice Department in connection with its handling of product safety issues.
The merger agreement, unless salvaged, would be one of the biggest ever to collapse because an acquiring company maintained that its target's value had fallen materially before the deal closed, the assertion J&J has made and Guidant has rejected, The Times reported.
In a statement, J&J said it planned on fighting Guidant's lawsuit, filed in U.S. District Court in Manhattan.
J&J has taken the position that Guidant's problems have affected its long-term outlook. Guidant has described any affect as short term.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Judge blocks FDA bid to allow generic Precedex

Judge blocks FDA bid to allow generic Precedex

The US District Court for Maryland granted Hospira a temporary restraining order (TRO) against FDA, after the agency determined that potential generic competitors of the company's injectable sedation drug Precedex ...

GSK drug gets aplastic anemia indication

GSK drug gets aplastic anemia indication

Promacta was previously indicated for chronic immune thrombocytopenia.

Five things for Pharma Marketers to know: Wednesday, August 27

Five things for Pharma Marketers to know: Wednesday, ...

Allergan sets a shareholder voting date, Novo describes the types of acquisitions it will consider, and the AstraZeneca-Pfizer talks can now reopen.